cannabis indica

Epilepsia

termo de indexação original: Epilepsy

O acervo do Cannabis Indica reúne 460 estudos científicos que tocam a condição Epilepsia, publicados entre 1839 e 2024. Pela leitura automatizada, 368 (80%) foram classificados como favoráveis, 54 (12%) como inconclusivos e 38 (8%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (235 estudos), seguido de estudo em animais (84). Os compostos mais presentes são CBD Farmacêutico, Tetraidrocanabinol (THC) e Anandamida (AEA). Aparece com frequência ao lado de Epilepsia — Síndrome de Dravet, Epilepsia — Lennox-Gastaut e Dor.

Estudos indexados
460
Período coberto
1839–2024
Favoráveis
368 · 80%
Inconclusivos
54 · 12%
Desfavoráveis
38 · 8%
Termo original
Epilepsy

O acervo em números

Tipo de estudo

Metanálise235
Estudo em Animais84
Ensaio Clínico62
Metanálise Clínica36
Ensaio Clínico Duplo-Cego23
Estudo Laboratorial20

Direção do resultado

Favorável368
Inconclusivo54
Desfavorável38

Por década

1830s1
1840s1
1850s1
1870s1
1890s1
1940s1
1970s9
1980s4
1990s2
2000s16
2010s137
2020s286

460 estudos

Filtrar e buscar no acervo →

Esta página mostra 334 dos 460 estudos indexados sobre o tema, dos mais recentes aos mais antigos. Abra o acervo com este filtro para percorrer todos, ou baixe a lista completa em JSON e CSV.

  1. 2024

    Cannabidiol-enriched oil for adult patients with drug-resistant epilepsy: Prospective clinical and electrophysiological study

    FavorávelEnsaio ClínicoTetraidrocanabinol (THC)
  2. 2024

    Cannabidiol: metabolism and clinical efficacy in epileptic patients

    FavorávelMetanáliseCBD Farmacêutico
  3. 2024

    Continuous spike-wave of slow sleep in a patient with KCNB1-related epilepsy responsive to highly purified cannabidiol: a case report and comparison with literature

    FavorávelMetanáliseAutismo
  4. 2024

    Dravet syndrome seizure frequency and clustering: Placebo-treated patients in clinical trials

    FavorávelMetanálise ClínicaEpilepsia — Síndrome de Dravet
  5. 2024

    Placebo response in patients with Dravet syndrome: Post-hoc analysis of two clinical trials

    InconclusivoMetanálise ClínicaEpilepsia — Síndrome de Dravet
  6. 2024

    The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials

    FavorávelMetanálise ClínicaEpilepsia — Síndrome de DravetCBD Farmacêutico
  7. 2024

    The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

    FavorávelMetanáliseDorInflamaçãoPsicoseEndocanabinoide (não especificado)+2
  8. 2024

    TRPV1 channel in the pathophysiology of epilepsy and its potential as a molecular target for the development of new antiseizure drug candidates

    FavorávelMetanálise
  9. 2023

    A case of clinical worsening after stereo-electroencephalographic-guided radiofrequency thermocoagulation in a patient with polymicrogyria

    FavorávelMetanálisePsicose
  10. 2023

    A Case of Panic Attacks Developing After 10 Years of Chronic Cannabis Use in a Patient With No Prior Psychiatric History

    DesfavorávelMetanáliseDorCâncerInflamaçãoTetraidrocanabinol (THC)Canabigerol (CBG)+13
  11. 2023

    A Rare Case of Cannabinoid Hyperemesis Syndrome Secondary to Cannabidiol for Refractory Epilepsy

  12. 2023

    A systematic review of cannabidiol trials in neurodevelopmental disorders

    FavorávelMetanálise ClínicaDorInflamaçãoAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+10
  13. 2023

    Biotechnological Fungal Platforms for the Production of Biosynthetic Cannabinoids

    FavorávelEstudo LaboratorialDorCâncerInflamaçãoTetraidrocanabinol (THC)THC Farmacêutico+25
  14. 2023

    Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - A Randomized Pilot Study

    FavorávelEnsaio Clínico Duplo-CegoDorCâncerDor — CrônicaTHC FarmacêuticoTHC:CBD Farmacêutico+8
  15. 2023

    Cannabidiol safety considerations: Development of a potential acceptable daily intake value and recommended upper intake limits for dietary supplement use

  16. 2023

    Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance

  17. 2023

    Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis

  18. 2023

    Could cannabinoids provide a new hope for ovarian cancer patients?

  19. 2023

    Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance

    FavorávelMetanáliseCâncerInflamaçãoAnsiedadeCanabigerol (CBG)Canabinol (CBN)+20
  20. 2023

    Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome

    FavorávelEnsaio ClínicoAnsiedadeSíndrome de Rett
  21. 2023

    Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review

  22. 2023

    Establishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids

    InconclusivoEstudo LaboratorialCâncerInflamaçãoPsicoseTetraidrocanabinol (THC)CBD Farmacêutico+3
  23. 2023

    Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom

  24. 2023

    Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    FavorávelMetanáliseEpilepsia — Síndrome de DravetQualidade de Vida
  25. 2023

    Instant Detection of Synthetic Cannabinoids on Physical Matrices, Implemented on a Low-Cost, Ultraportable Device

  26. 2023

    Medical Cannabis Received by Patients According to Qualifying Condition in a US State Cannabis Program: Product Choice, Dosing, and Age-Related Trends

    FavorávelMetanáliseDorCâncerDor — CrônicaTHC FarmacêuticoCBD Farmacêutico+16
  27. 2023

    Myoclonic super-refractory status epilepticus with favourable evolution in a teenager with FIRES: Is the association of vagus nerve stimulation and cannabidiol effective?

    FavorávelMetanáliseEpilepsia — FIRES
  28. 2023

    Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

    FavorávelMetanálise ClínicaEpilepsia — Síndrome de DravetCBD Farmacêutico
  29. 2023

    Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection

    InconclusivoMetanálise ClínicaDorCâncerAnsiedadeTHC FarmacêuticoTHC:CBD Farmacêutico+9
  30. 2023

    Recurrent Severe Burns Due to Cannabinoid Hyperemesis Syndrome

  31. 2023

    Reversible cerebral vasoconstriction syndrome associated with probable drug poisoning

  32. 2023

    Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials

    FavorávelMetanálise ClínicaEpilepsia — Lennox-GastautCBD Farmacêutico
  33. 2023

    The use of cannabidiol as a novel treatment for oral stereotypic behaviour (crib-biting) in a horse

    FavorávelEstudo em AnimaisDorInflamaçãoAnsiedadeEndocanabinoide (não especificado)+12
  34. 2023

    Toxic Tetrahydrocannabinol (THC) Dose in Pediatric Cannabis Edible Ingestions

  35. 2023

    Turning down the spice: tackling the problems of synthetic cannabinoids

  36. 2023

    Use of non-medical cannabis in epilepsy: A scoping review

  37. 2022

    A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)

  38. 2022

    A narrative review of molecular mechanism and therapeutic effect of Cannabidiol (CBD)

    FavorávelMetanáliseDorCâncerInflamação+5
  39. 2022

    A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication

  40. 2022

    A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoAnsiedadeAnandamida (AEA)Palmitoiletanolamida (PEA)+5
  41. 2022

    A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment

    FavorávelMetanáliseDorCâncerAnsiedadeAnandamida (AEA)Tetraidrocanabinol (THC)+25
  42. 2022

    A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development

    FavorávelMetanálise
  43. 2022

    Acute pancreatitis as a rare adverse event among cannabis users: A systematic review

    DesfavorávelMetanáliseDorInflamaçãoEfeitos Adversos da CannabisAnandamida (AEA)+16
  44. 2022

    Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial

    InconclusivoEnsaio Clínico Duplo-CegoEpilepsia — Síndrome de DravetEpilepsia — Lennox-Gastaut
  45. 2022

    Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services

  46. 2022

    Adverse events of recreational cannabis use during pregnancy reported to the French Addictovigilance Network between 2011 and 2020

  47. 2022

    Antiseizure Effects of Cannabidiol Leading to Increased Peroxisome Proliferator-Activated Receptor Gamma Levels in the Hippocampal CA3 Subfield of Epileptic Rats

    FavorávelEstudo em Animais
  48. 2022

    Beta-caryophyllene attenuates short-term recurrent seizure activity and blood-brain-barrier breakdown after pilocarpine-induced status epilepticus in rats

    FavorávelEstudo em Animais
  49. 2022

    Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy

  50. 2022

    Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force

    FavorávelMetanálise ClínicaEfeitos Adversos da CannabisGestação
  51. 2022

    Cannabidiol activates neuronal Kv7 channels

    FavorávelEstudo Laboratorial
  52. 2022

    Cannabidiol for the treatment of autism spectrum disorder: hope or hype?

  53. 2022

    Cannabidiol in canine epilepsy

    InconclusivoMetanáliseDorCâncerInflamaçãoÁcido Canabidiólico (CBD-a)+7
  54. 2022

    Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study

  55. 2022

    Cannabidiol Increases Seizure Resistance and Improves Behavior in an Scn8a Mouse Model

    FavorávelEstudo em AnimaisTranstornos de ComportamentoAutismoTDA e TDAH
  56. 2022

    Cannabinoids in rheumatology: Friend, foe or a bystander?

  57. 2022

    Cannabinoids: Therapeutic Use in Clinical Practice

  58. 2022

    Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug

  59. 2022

    Cannabis in Palliative Care: A Systematic Review of Current Evidence

    InconclusivoMetanáliseCâncerInsônia e Distúrbios do SonoNáusea e Vômito+6
  60. 2022

    Cannabis Use and the Endocannabinoid System: A Clinical Perspective

  61. 2022

    Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis

  62. 2022

    Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study

    FavorávelEnsaio Clínico Duplo-CegoTetraidrocanabinol (THC)
  63. 2022

    Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review

    FavorávelMetanáliseDorCâncerInflamaçãoAnandamida (AEA)Tetraidrocanabinol (THC)+28
  64. 2022

    Current Cannabidiol Safety: A Review

    FavorávelMetanáliseDorCâncerInflamação+10
  65. 2022

    Cys-loop receptors on cannabinoids: All high?

    FavorávelMetanáliseDorDor — Crônica
  66. 2022

    Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?

  67. 2022

    E-cigarette vaping associated acute lung injury (EVALI): state of science and future research needs

    DesfavorávelMetanáliseCâncerAnsiedadeDoenças Cardiovasculares (DCV)+16
  68. 2022

    Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review

    FavorávelMetanáliseAnsiedadeObesidadeDiabetesTetraidrocanabinol (THC)+5
  69. 2022

    Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial

    FavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisAnsiedadeDisfunção CognitivaTetraidrocanabinol (THC)+1
  70. 2022

    Effects of Epidiolex® (Cannabidiol) on seizure-related emergency department visits and hospital admissions: A retrospective cohort study

    FavorávelMetanáliseCBD Farmacêutico
  71. 2022

    Effects of short-term environmental stresses on the onset of cannabinoid production in young immature flowers of industrial hemp (Cannabis sativa L.)

  72. 2022

    Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis

    FavorávelMetanálise ClínicaEpilepsia — Síndrome de Dravet
  73. 2022

    Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis

    FavorávelMetanálise ClínicaEpilepsia — Lennox-Gastaut
  74. 2022

    Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial

    FavorávelEnsaio ClínicoSíndrome de RettCanabidivarina (CBDV)
  75. 2022

    Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap

  76. 2022

    Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story?

  77. 2022

    Epilepsy and cannabis: so near, yet so far

    DesfavorávelMetanáliseEpilepsia — Síndrome de DravetEpilepsia — Lennox-Gastaut
  78. 2022

    Evaluation of the Possible Anticonvulsant Effect of Δ 9-Tetrahydrocannabinolic Acid in Murine Seizure Models

    InconclusivoEstudo em AnimaisÁcido Tetraidrocanabinólico (THC-a)
  79. 2022

    Geraniol enhances inhibitory inputs to the paraventricular thalamic nucleus and induces sedation in mice

    FavorávelEstudo em AnimaisInsônia e Distúrbios do Sono
  80. 2022

    Herbal Approaches to Pediatric Functional Abdominal Pain

    InconclusivoMetanáliseDorInflamaçãoDor — CrônicaTHC Farmacêutico+10
  81. 2022

    Impact of Antiseizure Medications on Appetite and Weight in Children

    InconclusivoMetanálise ClínicaPerda de Apetite
  82. 2022

    In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters

  83. 2022

    Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors

  84. 2022

    Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy

    FavorávelEnsaio ClínicoEncefalite e Mielite
  85. 2022

    Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  86. 2022

    Modulation of Recombinant Human T-Type Calcium Channels by Δ 9-Tetrahydrocannabinolic Acid In Vitro

    FavorávelEstudo LaboratorialDorDoenças NeurodegenerativasÁcido Tetraidrocanabinólico (THC-a)
  87. 2022

    Movement Disorders Secondary to Novel Antiseizure Medications in Pediatric Populations: A Systematic Review and Meta-analysis of Risk

  88. 2022

    Neuroplastic alterations in cannabinoid receptors type 1 (CB1) in animal models of epileptic seizures

    FavorávelMetanáliseEndocanabinoide (não especificado)
  89. 2022

    Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders

  90. 2022

    Observational study of medical marijuana as a treatment for treatment-resistant epilepsies

    InconclusivoMetanáliseEpilepsia — Lennox-GastautTetraidrocanabinol (THC)
  91. 2022

    Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome

    FavorávelEstudo em AnimaisEpilepsia — Síndrome de DravetÁcido Canabigerólico (CBG-a)
  92. 2022

    Pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain, and allodynia using a model mimicking acute pain in healthy adults in a randomized trial (CANAB II)

    DesfavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDependência — OpioidesCBD Farmacêutico
  93. 2022

    Persistent Diarrhea and Eosinophilic Esophagitis Resulting From Chronic Cannabidiol Usage for Refractory Epilepsy

  94. 2022

    Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: a pilot study

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDepressãoTetraidrocanabinol (THC)Monoacilglicerol Lipase (MAGL)+2
  95. 2022

    Pharmacological effects of cannabidiol by transient receptor potential channels

    FavorávelMetanáliseDorCâncerInflamação+5
  96. 2022

    Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot

  97. 2022

    Practical Considerations for the Use of Cannabis in Cancer Pain Management—What a Medical Oncologist Should Know

  98. 2022

    Prescription cannabidiol for seizure disorder management: Initial drug-drug interaction management by specialty pharmacists

  99. 2022

    Protective Effects of Cannabidiol on Chemotherapy-Induced Oral Mucositis via the Nrf2/Keap1/ARE Signaling Pathways

    FavorávelEstudo em AnimaisCâncerInflamaçãoDoenças Cardiovasculares (DCV)+6
  100. 2022

    Quantitative electroencephalographic analysis as a potential biomarker of response to treatment with cannabidiol

  101. 2022

    Recreational cannabis legalizations associated with reductions in prescription drug utilization among Medicaid enrollees

    FavorávelMetanáliseDorAnsiedadeDor — Crônica+3
  102. 2022

    Serum Cannabinoid 24 h and 1 Week Steady State Pharmacokinetic Assessment in Cats Using a CBD/CBDA Rich Hemp Paste

    InconclusivoEstudo em AnimaisDorCâncerAnsiedadeTetraidrocanabinol (THC)Ácido Canabidiólico (CBD-a)+3
  103. 2022

    Shifting the Paradigm on Cannabis Safety

    DesfavorávelMetanáliseCâncerInflamaçãoEfeitos Adversos da CannabisCBD Farmacêutico+16
  104. 2022

    Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Ayahuasca Use in a Satanic Ritual: A Case Report

  105. 2022

    Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report

  106. 2022

    The Cannabis-Induced Epigenetic Regulation of Genes Associated with Major Depressive Disorder

  107. 2022

    The effect of medical cannabis on cognitive functions: a systematic review

    DesfavorávelMetanálise ClínicaDorCâncerEfeitos Adversos da CannabisTHC:CBD FarmacêuticoCBD Farmacêutico+11
  108. 2022

    The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials

    InconclusivoMetanálise ClínicaDependência QuímicaAnsiedadePsicoseTetraidrocanabinol (THC)CBD Farmacêutico+1
  109. 2022

    The Long-Term Effectiveness and Safety of Cannabidiol-Enriched Oil in Children With Drug-Resistant Epilepsy

    FavorávelMetanálise
  110. 2022

    The Medicinal Natural Products of Cannabis sativa Linn.: A Review

  111. 2022

    The Potential Proconvulsant Effects of Cannabis: a Scoping Review

    DesfavorávelMetanáliseEfeitos Adversos da CannabisTetraidrocanabinol (THC)
  112. 2022

    The Role of the Possible Receptors and Intracellular Pathways in Protective Effect of Exogenous Anandamide in Kindling Model of Epilepsy

    FavorávelEstudo em AnimaisAnandamida (AEA)
  113. 2022

    Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

  114. 2022

    Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events in Tuberous Sclerosis Complex: Post Hoc Analysis of Randomized Controlled Phase 3 Trial GWPCARE6

    InconclusivoMetanálise
  115. 2022

    Treatment of Ovarian Hyperstimulation Syndrome in a Mouse Model by Cannabidiol, an Angiogenesis Pathway Inhibitor

    FavorávelEstudo em AnimaisDorCâncerInflamação+16
  116. 2022

    TRPV1: A Common Denominator Mediating Antinociceptive and Antiemetic Effects of Cannabinoids

  117. 2022

    Use of cannabidiol in the treatment of epilepsy

    FavorávelMetanálise
  118. 2022

    Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex

  119. 2022

    Use of cannabis in the treatment of animals: a systematic review of randomized clinical trials

    FavorávelMetanálise ClínicaDorDor — CrônicaTranstornos de Comportamento+3
  120. 2021

    A 3-year-old child with multi-drug resistant epilepsy responding to pharmacological and nonpharmacological treatments

    FavorávelMetanálise
  121. 2021

    A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019

    InconclusivoMetanáliseDorCâncerDor — CrônicaTHC FarmacêuticoCBD Farmacêutico+9
  122. 2021

    A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects

    DesfavorávelEnsaio ClínicoEpilepsia — Lennox-GastautCBD Farmacêutico
  123. 2021

    A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures

    InconclusivoEnsaio Clínico Duplo-CegoCanabidivarina (CBDV)
  124. 2021

    A Review of Hemp as Food and Nutritional Supplement

    FavorávelMetanáliseAnsiedadeEstresse OxidativoSíndrome Metabólica+2
  125. 2021

    A review on the traditional uses, phytochemistry, and pharmacological activities of clove basil (Ocimum gratissimum L.)

    FavorávelMetanáliseInflamaçãoInfecções Bacterianas
  126. 2021

    A validated method for the simultaneous quantification of cannabidiol, Δ9 -tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trial

    FavorávelEstudo LaboratorialAnsiedadeDor — CrônicaCanabicromeno (CBC)
  127. 2021

    Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial

    FavorávelEnsaio ClínicoEpilepsia — Síndrome de Dravet
  128. 2021

    Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex

    FavorávelEnsaio Clínico Duplo-CegoCBD Farmacêutico
  129. 2021

    Allosteric modulation of the cannabinoid 2 receptor confers seizure resistance in mice

    FavorávelEstudo em AnimaisCanabinoide Sintético (não especificado)
  130. 2021

    An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models

  131. 2021

    Anti-seizure medications for Lennox-Gastaut syndrome

    InconclusivoMetanáliseEpilepsia — Lennox-GastautCBD Farmacêutico
  132. 2021

    Anticonvulsant activity of β-caryophyllene in association with pregabalin in a seizure model in rats

    FavorávelEstudo em Animais
  133. 2021

    Anticonvulsant, Anxiolytic and Antidepressant Properties of the β-caryophyllene in Swiss Mice: Involvement of Benzodiazepine-GABAAergic, Serotonergic and Nitrergic Systems

    FavorávelEstudo em AnimaisAnsiedadeDepressão
  134. 2021

    Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome

  135. 2021

    Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment

    DesfavorávelEstudo LaboratorialInflamaçãoEstresse Oxidativo
  136. 2021

    Cannabidiol (CBD) and cognition in epilepsy

    FavorávelMetanálise
  137. 2021

    Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial

  138. 2021

    Cannabidiol and mental health: possibilities, uncertainties, and controversies for addiction treatment

    InconclusivoMetanáliseDependência QuímicaAnsiedadeDepressão+10
  139. 2021

    Cannabidiol and Neurodevelopmental Disorders in Children

  140. 2021

    Cannabidiol and Sodium Channel Pharmacology: General Overview, Mechanism, and Clinical Implications

    FavorávelMetanáliseEpilepsia — Síndrome de Dravet
  141. 2021

    Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain

  142. 2021

    Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials

    FavorávelEnsaio Clínico Duplo-CegoCBD Farmacêutico
  143. 2021

    Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action

    FavorávelMetanáliseCâncerDoenças NeurodegenerativasEsclerose Múltipla+1
  144. 2021

    Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

  145. 2021

    Cannabidiol in the Treatment of Epilepsy

  146. 2021

    Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research

    FavorávelMetanálise
  147. 2021

    Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review

  148. 2021

    Cannabidiol modifies the seizure expression and effects of antiseizure drugs in a rat model of recurrent severe seizures

    FavorávelEstudo em Animais
  149. 2021

    Cannabidiol reduces soman-induced lethality and seizure severity in female plasma carboxylesterase knockout mice treated with midazolam

    FavorávelEstudo em Animais
  150. 2021

    Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders

    FavorávelMetanálise
  151. 2021

    Cannabidiol treatment of severe refractory epilepsy in children and young adults

  152. 2021

    Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients

    FavorávelEnsaio Clínico
  153. 2021

    Cannabidiol-enriched oil in children and adults with treatment-resistant epilepsy-does tolerance exist?

    DesfavorávelMetanálise
  154. 2021

    Cannabidiol: pharmacology and therapeutic targets

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+4
  155. 2021

    Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures

    FavorávelEstudo em AnimaisÁcido Canabidiólico (CBD-a)
  156. 2021

    Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy

    FavorávelEstudo em AnimaisEpilepsia — Síndrome de DravetÁcido Canabigerólico (CBG-a)
  157. 2021

    Cannabinoid control of hippocampal functions: the where matters

  158. 2021

    Cannabinoid hyperemesis syndrome can be relieved by warm baths

    DesfavorávelMetanáliseDorEfeitos Adversos da CannabisDependência — Cannabis+2
  159. 2021

    Cannabinoids in Audiogenic Seizures: From Neuronal Networks to Future Perspectives for Epilepsy Treatment

    FavorávelMetanáliseEndocanabinoide (não especificado)
  160. 2021

    Cannabis Use among Cancer Survivors amid the COVID-19 Pandemic: Results from the COVID-19 Cannabis Health Study

    InconclusivoEnsaio ClínicoCâncerInsônia e Distúrbios do SonoNáusea e Vômito+3
  161. 2021

    Case Report: Lennox-Gastaut Epileptic Encephalopathy Responsive to Cannabidiol Treatment Associated With a Novel de novo Mosaic SHANK1 Variant

  162. 2021

    Chronic cannabidiol (CBD) administration induces anticonvulsant and antiepileptogenic effects in a genetic model of epilepsy

    FavorávelEstudo em Animais
  163. 2021

    Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy

    FavorávelEnsaio Clínico
  164. 2021

    Combined Antiseizure Efficacy of Cannabidiol and Clonazepam in a Conditional Mouse Model of Dravet Syndrome

    FavorávelEstudo em AnimaisEpilepsia — Síndrome de Dravet
  165. 2021

    Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101

    DesfavorávelEstudo em AnimaisDorInflamaçãoEfeitos Adversos da Cannabis+5
  166. 2021

    Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations

  167. 2021

    Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy

    FavorávelMetanálise
  168. 2021

    Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics

    InconclusivoMetanáliseAnsiedadeEsclerose MúltiplaTEPT
  169. 2021

    Current review of hemp-based medicines in dogs

    FavorávelMetanáliseArtriteAplicações VeterináriasArtrite — Osteoartrite
  170. 2021

    Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol

  171. 2021

    Development of central precocious puberty following cannabinoid use for paediatric epilepsy: causal or coincidence?

    FavorávelMetanálise
  172. 2021

    Dravet syndrome

    FavorávelMetanáliseEpilepsia — Síndrome de Dravet
  173. 2021

    Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study

  174. 2021

    Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

  175. 2021

    Efficacy and safety of paediatric medicinal cannabis use: A scoping review

  176. 2021

    Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Approaches and Recent Advances

    InconclusivoMetanáliseCanabigerol (CBG)Canabidivarina (CBDV)
  177. 2021

    Endocannabinoid-serotonin systems interaction in health and disease

  178. 2021

    Epileptic Phenotype and Cannabidiol Efficacy in a Williams–Beuren Syndrome Patient With Atypical Deletion: A Case Report

  179. 2021

    Evidence for an increase in cannabis use in Iran - A systematic review and trend analysis

  180. 2021

    Exacerbation of eyelid myoclonia in patients with epilepsy and eyelid myoclonia receiving cannabidiol

    DesfavorávelMetanálise
  181. 2021

    Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment

    InconclusivoMetanáliseAnandamida (AEA)
  182. 2021

    From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?

    FavorávelMetanálise
  183. 2021

    Functional Connectivity Derived From Electroencephalogram in Pharmacoresistant Epileptic Encephalopathy Using Cannabidiol as Adjunctive Antiepileptic Therapy

    FavorávelEnsaio ClínicoTHC:CBD Farmacêutico
  184. 2021

    Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome

    FavorávelMetanálise ClínicaEpilepsia — Síndrome de DravetEpilepsia — Lennox-Gastaut
  185. 2021

    Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study

    FavorávelEnsaio ClínicoDorAnsiedadeDor — CrônicaCBD Farmacêutico+3
  186. 2021

    Interaction of cannabidiol with other antiseizure medications: A narrative review

    FavorávelMetanálise
  187. 2021

    Lethal case of myocardial ischemia following overdose of the synthetic cannabinoid ADB-FUBINACA

  188. 2021

    Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial

  189. 2021

    Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial

    FavorávelEnsaio Clínico Duplo-CegoEpilepsia — Lennox-GastautCBD Farmacêutico
  190. 2021

    Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy

    FavorávelEnsaio ClínicoCBD Farmacêutico
  191. 2021

    Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsy

    FavorávelEnsaio ClínicoCBD Farmacêutico
  192. 2021

    Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients

    FavorávelEnsaio Clínico
  193. 2021

    Medicinal applications of cannabis/cannabinoids

    InconclusivoMetanáliseDorInsônia e Distúrbios do SonoCBD Farmacêutico
  194. 2021

    Mixed methods study of the potential therapeutic benefits from medical cannabis for patients in Florida

    FavorávelMetanáliseDorDor — CrônicaDepressão+6
  195. 2021

    Myrcene—What Are the Potential Health Benefits of This Flavouring and Aroma Agent?

    FavorávelMetanáliseDorCâncerInflamaçãoEndocanabinoide (não especificado)+9
  196. 2021

    Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

  197. 2021

    Neuroprotective Potential of Limonene and Limonene Containing Natural Products

    FavorávelMetanáliseAnsiedadeDoenças NeurodegenerativasEsclerose Múltipla+2
  198. 2021

    New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol

  199. 2021

    Perspectives of pediatric oncologists and palliative care physicians on the therapeutic use of cannabis in children with cancer

    FavorávelMetanáliseDorCâncerDor — Crônica+7
  200. 2021

    Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy

    InconclusivoEnsaio ClínicoEncefalite e Mielite
  201. 2021

    Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

  202. 2021

    Potential Benefit of Add-on Δ9-Tetrahydrocannabinol in Pediatric Drug-Resistant Epilepsy: A Case Series

    FavorávelMetanálise
  203. 2021

    Potential therapeutic uses of cannabinoids to treat behavioural problems in children and adolescents with developmental disorders

    FavorávelMetanáliseEfeitos Adversos da CannabisAnsiedadeDepressão+8
  204. 2021

    Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

    FavorávelEstudo em AnimaisEpilepsia — Síndrome de Dravet
  205. 2021

    Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome

  206. 2021

    Safety and tolerability of escalating cannabinoid doses in healthy cats

  207. 2021

    Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial

    FavorávelEnsaio ClínicoEncefalite e Mielite
  208. 2021

    Seizure and Interictal Electroencephalographic (EEG) Changes with Cannabinoid Concentrate Use

    DesfavorávelMetanálise
  209. 2021

    Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol

  210. 2021

    The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets

    FavorávelMetanáliseAnsiedadeEsquizofrenia
  211. 2021

    The long-term efficacy of cannabidiol in the treatment of refractory epilepsy

    FavorávelMetanáliseCBD Farmacêutico
  212. 2021

    The perceived effects of cannabis products in the management of seizures in CDKL5 Deficiency Disorder

    FavorávelEnsaio Clínico
  213. 2021

    Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder

    InconclusivoMetanáliseAutismoCanabidivarina (CBDV)
  214. 2021

    Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials

    FavorávelMetanálise ClínicaEpilepsia — Lennox-GastautCBD Farmacêutico
  215. 2021

    Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials

  216. 2021

    Treatment Guidelines for Rare, Early-Onset, Treatment-Resistant Epileptic Conditions: A Literature Review on Dravet Syndrome, Lennox-Gastaut Syndrome and CDKL5 Deficiency Disorder

    InconclusivoMetanálise ClínicaEpilepsia — Síndrome de DravetEpilepsia — Lennox-Gastaut
  217. 2021

    Two-center experience of cannabidiol use in adults with Dravet syndrome

  218. 2021

    UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations

    InconclusivoEstudo LaboratorialCBD Farmacêutico
  219. 2021

    Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland

  220. 2021

    White matter integrity after cannabidiol administration for treatment resistant epilepsy

    FavorávelEnsaio ClínicoCBD Farmacêutico
  221. 2021

    Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats

    FavorávelEstudo em AnimaisTetraidrocanabivarina (THCV)
  222. 2020

    A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?

    FavorávelMetanálise
  223. 2020

    A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoAnsiedadeNáusea e Vômito
  224. 2020

    A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam

    FavorávelEnsaio Clínico Duplo-CegoEpilepsia — Síndrome de DravetEpilepsia — Lennox-GastautCBD Farmacêutico
  225. 2020

    A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment

  226. 2020

    A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

    FavorávelEnsaio Clínico Duplo-CegoEpilepsia — Síndrome de DravetEpilepsia — Lennox-GastautCBD Farmacêutico
  227. 2020

    A systematic review of minor phytocannabinoids with promising neuroprotective potential

  228. 2020

    Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety

    FavorávelMetanálise ClínicaEpilepsia — Síndrome de Dravet
  229. 2020

    Anandamide Metabolites Protect against Seizures through the TRP Channel Water Witch in Drosophila melanogaster

    FavorávelEstudo em AnimaisAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  230. 2020

    Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent

    FavorávelEstudo em Animais
  231. 2020

    Barriers in accessing medical cannabis for children with drug-resistant epilepsy in Canada: A qualitative study

    FavorávelMetanálise
  232. 2020

    Behavioral and Molecular Effects Induced by Cannabidiol and Valproate Administration in the GASH/Sal Model of Acute Audiogenic Seizures

    InconclusivoEstudo em AnimaisAnandamida (AEA)
  233. 2020

    Cannabidiol (CBD)

    FavorávelMetanáliseInflamaçãoAnsiedadeDoenças Neurodegenerativas+4
  234. 2020

    Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions

    FavorávelEstudo LaboratorialEstresse Oxidativo
  235. 2020

    Cannabidiol anticonvulsant effect is mediated by the PI3Kγ pathway

    FavorávelEstudo em Animais
  236. 2020

    Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice

    FavorávelEstudo em AnimaisDorAnsiedadeNáusea e VômitoÁcido Canabidiólico (CBD-a)
  237. 2020

    Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects

  238. 2020

    Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials

  239. 2020

    Cannabidiol for epilepsy (Lennox-Gastaut syndrome, Dravet syndrome)

  240. 2020

    Cannabidiol inhibits febrile seizure by modulating AMPA receptor kinetics through its interaction with the N-terminal domain of GluA1/GluA2

    FavorávelEstudo em AnimaisEpilepsia — FIRES
  241. 2020

    Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy

    FavorávelEnsaio ClínicoCBD Farmacêutico
  242. 2020

    Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions

    FavorávelMetanáliseTetraidrocanabinol (THC)
  243. 2020

    Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects

    FavorávelMetanálise
  244. 2020

    Cannabinoids Rescue Cocaine-Induced Seizures by Restoring Brain Glycine Receptor Dysfunction

    FavorávelEstudo em AnimaisDependência QuímicaDependência — Cocaína
  245. 2020

    Cannabinoids: A New Perspective on Epileptogenesis and Seizure Treatment in Early Life in Basic and Clinical Studies

    FavorávelMetanálise
  246. 2020

    Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish

    FavorávelEstudo em AnimaisCanabinol (CBN)
  247. 2020

    Cannabis for Pediatric Epilepsy

    FavorávelMetanálise
  248. 2020

    Cannabis sativa: Much more beyond Δ 9-tetrahydrocannabinol

    FavorávelMetanáliseDorDor — CrônicaDoenças Neurodegenerativas+1
  249. 2020

    Cannabis Treatment in Children with Epilepsy: Practices of Canadian Neurologists

    FavorávelMetanálise
  250. 2020

    Cannabis, More Than the Euphoria: Its Therapeutic Use in Drug-Resistant Epilepsy

    FavorávelMetanálise
  251. 2020

    CB2R orchestrates neuronal autophagy through regulation of the mTOR signaling pathway in the hippocampus of developing rats with status epilepticus

    FavorávelEstudo em AnimaisCanabinoides Sintéticos AM-xCanabinoides Sintéticos JWH-x
  252. 2020

    Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency

  253. 2020

    Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy

  254. 2020

    Development of cannabidiol as a treatment for severe childhood epilepsies

    FavorávelMetanálise
  255. 2020

    Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials

  256. 2020

    Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial

    FavorávelEnsaio Clínico Duplo-CegoEpilepsia — Síndrome de DravetEpilepsia — Lennox-GastautCBD Farmacêutico
  257. 2020

    Drug-Drug Interactions Between Cannabidiol and Lithium

  258. 2020

    Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis

    FavorávelMetanáliseEpilepsia — Síndrome de Dravet
  259. 2020

    Effect of Cannabinoids on Electroencephalography of a Child with Lennox-Gastaut Syndrome

  260. 2020

    Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis

    FavorávelMetanálise Clínica
  261. 2020

    Ending the pain of children with severe epilepsy? An audit of the impact of medical cannabis in 10 patients

    FavorávelMetanálise
  262. 2020

    Endocannabinoid System and Cannabinoid 1 Receptors in Patients With Pharmacoresistant Temporal Lobe Epilepsy and Comorbid Mood Disorders

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  263. 2020

    Epilepsy and cannabidiol: a guide to treatment

    FavorávelMetanálise Clínica
  264. 2020

    Interactions between cannabidiol and Δ 9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome

    FavorávelEstudo em AnimaisEpilepsia — Síndrome de Dravet
  265. 2020

    Inverse Agonism of Cannabinoid Receptor Type 2 Confers Anti-inflammatory and Neuroprotective Effects Following Status Epileptics

    FavorávelEstudo em Animais
  266. 2020

    Lennox–Gastaut Syndrome: Perspective of a Parent and a Physician

    FavorávelMetanáliseEpilepsia — Lennox-GastautCBD Farmacêutico
  267. 2020

    Mapping cannabis potency in medical and recreational programs in the United States

    DesfavorávelMetanáliseDorAnsiedadeDor — CrônicaTetraidrocanabinol (THC)+4
  268. 2020

    Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

  269. 2020

    Neural Stem Cells and Cannabinoids in the Spotlight as Potential Therapy for Epilepsy

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  270. 2020

    Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease

    FavorávelMetanáliseDoença de Alzheimer
  271. 2020

    Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy

  272. 2020

    Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model

  273. 2020

    Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission?

    InconclusivoMetanáliseAnsiedadeDoença de AlzheimerDoença de Parkinson+2
  274. 2020

    Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome

  275. 2020

    Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and Epilepsy

    FavorávelMetanálise
  276. 2020

    Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study

    FavorávelEnsaio Clínico
  277. 2020

    Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study

    DesfavorávelEnsaio ClínicoCanabinoide Sintético (não especificado)
  278. 2020

    Terpenes/Terpenoids in Cannabis: Are They Important?

    FavorávelMetanáliseDorCâncerInflamação+10
  279. 2020

    The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights

    FavorávelMetanálise
  280. 2020

    The Endocannabinoid System and Synthetic Cannabinoids in Preclinical Models of Seizure and Epilepsy

  281. 2020

    The Endocannabinoid System May Modulate Sleep Disorders in Aging

  282. 2020

    The proposed mechanisms of action of CBD in epilepsy

    FavorávelMetanálise
  283. 2020

    The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials

    InconclusivoMetanálise Clínica
  284. 2020

    The Use of Cannabis as a Treatment for Epilepsy in Adult Patients: Are Side Effects a Limitation of Use?

    FavorávelMetanálise
  285. 2020

    The use of medical grade cannabis in Italy for drug-resistant epilepsy: a case series

    FavorávelMetanáliseTetraidrocanabinol (THC)
  286. 2020

    Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies

    InconclusivoMetanáliseDorDependência QuímicaInflamação+6
  287. 2019

    A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety

    InconclusivoMetanáliseDorCâncerEpilepsia — Lennox-GastautCBD Farmacêutico+1
  288. 2019

    A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

  289. 2019

    A systematic review of cannabidiol dosing in clinical populations

    FavorávelMetanálise ClínicaDorDependência — CannabisAnsiedade+14
  290. 2019

    Anticonvulsant Essential Oils and Their Relationship with Oxidative Stress in Epilepsy

    FavorávelMetanáliseEstresse Oxidativo
  291. 2019

    Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?

    DesfavorávelMetanáliseEpilepsia — Síndrome de DravetEpilepsia — Lennox-Gastaut
  292. 2019

    Can we teach old drugs new tricks?-Repurposing of neuropharmacological drugs for inflammatory skin diseases

    FavorávelMetanáliseInflamaçãoDepressãoDependência — Opioides+14
  293. 2019

    Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome

    InconclusivoMetanáliseEpilepsia — Síndrome de DravetEpilepsia — Lennox-Gastaut
  294. 2019

    Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study

    FavorávelEnsaio Clínico Duplo-CegoEpilepsia — Síndrome de DravetEpilepsia — Lennox-GastautCBD Farmacêutico
  295. 2019

    Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

  296. 2019

    Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy

  297. 2019

    Cannabinoid therapy in epilepsy

    InconclusivoMetanáliseEpilepsia — Síndrome de DravetEpilepsia — Lennox-Gastaut
  298. 2019

    Cannabinoids for drug-resistant seizures in a critically ill patient-Case report and literature review

    FavorávelMetanáliseEpilepsia — Lennox-Gastaut
  299. 2019

    Cannabis and Epilepsy

  300. 2019

    Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder

  301. 2019

    Cannabis Use Disorder and Epilepsy: A Cross-National Analysis of 657 072 Hospitalized Patients

    InconclusivoMetanáliseDependência — Cannabis
  302. 2019

    Cannabis use is both independently associated with and mediates worse psychosocial health in patients with epilepsy

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDepressão
  303. 2019

    Comparative Study of Alpha- And Beta-Pinene Effect on PTZ-induced Convulsions in Mice

    InconclusivoEstudo em Animais
  304. 2019

    Drug-drug Interaction Studies with Coadministration of Cannabidiol (CBD) and Clobazam, Valproate, Stiripentol or Midazolam in Healthy Volunteers and Adults with Epilepsy

    InconclusivoEnsaio Clínico
  305. 2019

    Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy

    InconclusivoMetanálise
  306. 2019

    Marijuana use among patients with epilepsy at a tertiary care center

    InconclusivoMetanálise
  307. 2019

    Prospective evaluation of oral cannabis extracts in children with epilepsy

    InconclusivoEnsaio Clínico
  308. 2019

    Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials

    FavorávelMetanálise Clínica
  309. 2018

    Cannabidiol Regulates Long Term Potentiation Following Status Epilepticus: Mediation by Calcium Stores and Serotonin.

    FavorávelEstudo em Animais
  310. 2018

    Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.

    FavorávelEnsaio Clínico
  311. 2018

    Pharmacological characterization of the cannabinoid receptor 2 agonist, β-caryophyllene on seizure models in mice.

    FavorávelEstudo em Animais
  312. 2017

    Assessing the role of serotonergic receptors in cannabidiol's anticonvulsant efficacy.

    FavorávelEstudo em Animais
  313. 2017

    Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy?

    FavorávelMetanálise
  314. 2017

    Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP)

    FavorávelEstudo em Animais
  315. 2017

    Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.

    FavorávelMetanálise
  316. 2017

    Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy

    FavorávelMetanálise
  317. 2016

    Anticonvulsant activity of β-caryophyllene against pentylenetetrazol-induced seizures.

    FavorávelEstudo em Animais
  318. 2016

    Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.

    FavorávelEnsaio Clínico
  319. 2016

    Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

    FavorávelEnsaio Clínico
  320. 2016

    Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure.

    FavorávelEstudo em Animais
  321. 2016

    CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

    FavorávelMetanálise
  322. 2016

    From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?

    FavorávelMetanálise
  323. 2016

    Marijuana use in adults admitted to a Canadian epilepsy monitoring unit.

    FavorávelMetanálise
  324. 2016

    Plant-Derived and Endogenous Cannabinoids in Epilepsy.

    FavorávelMetanálise
  325. 2016

    The Pharmacological Basis of Cannabis Therapy for Epilepsy.

    FavorávelMetanálise
  326. 2016

    Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol.

    FavorávelMetanáliseTetraidrocanabinol (THC)
  327. 2015

    Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy.

    FavorávelMetanáliseEndocanabinoide (não especificado)
  328. 2012

    Cannabinoids for epilepsy

    InconclusivoMetanálise Clínica
  329. 2010

    Anticonvulsant and anxiolytic evaluation of leaf extracts of Ocimum gratissimum, a culinary herb

    FavorávelEstudo em AnimaisAnsiedade
  330. 2010

    Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy.

    FavorávelEnsaio ClínicoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  331. 2006

    Evolution of the Anticonvulsant Activity of α-Terpineol

    FavorávelEstudo em Animais
  332. 2003

    International Association for Cannabis as Medicine.

    FavorávelMetanálise
  333. 1995

    Effects of Linalool on glutamatergic system in the rat cerebral cortex.

    FavorávelEstudo em AnimaisAnsiedade
  334. 1980

    Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients.

    FavorávelEnsaio Clínico Duplo-Cego

Continue por aqui

Perguntas frequentes

Quantos estudos sobre epilepsia estão indexados no acervo?
São 460 estudos, publicados entre 1839 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 235 · Estudo em Animais: 84 · Ensaio Clínico: 62 · Metanálise Clínica: 36 · Ensaio Clínico Duplo-Cego: 23 · Estudo Laboratorial: 20. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 368 favoráveis, 54 inconclusivos e 38 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Epilepsia — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/epilepsia/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Epilepsia — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/epilepsia/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.